Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, August 21, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Edwin Zhang Reiterated (CALT) at Strong Buy and Held Target at $50 on, Aug 21st, 2023
Edwin Zhang of HC Wainwright & Co., Reiterated "Calliditas Therapeutics AB (publ)" (CALT) at Strong Buy and Held Target at $50 on, Aug 21st, 2023.
Edwin has made no other calls on CALT in the last 4 months.
There is 1 other peer that has a rating on CALT. Out of the 1 peers that are also analyzing CALT, all agrees with Edwin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vamil Divan of "Guggenheim" Maintained at Hold with Decreased Target to $18 on, Friday, August 18th, 2023
